

RECEIVED  
CENTRAL FAX CENTER

AUG 15 2006

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3 (canceled).

Claim 4. (previously presented) An isolated nucleic acid encoding at least one isolated mammalian anti-dual integrin antibody having at least one variable region comprising SEQ ID NO: 7 or 8.

Claim 5. (previously presented). An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 4.

Claim 6. (previously presented) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 5.

Claim 7. (previously presented) A host cell according to claim 6, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

Claim 8. (previously presented) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid according to claim 4 under conditions in vitro, in vivo or in situ, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claims 9-23 (canceled)

Claim 24. (amended) An isolated nucleic acid encoding at least one isolated mammalian anti-dual integrin antibody comprising either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NOS:1, 2, and 3; ~~or~~ and (ii) all of the light chain CDR amino acids sequences of SEQ ID NOS:4, 5, and 6.

Claim 25. (amended) An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 4 24.

Claim 26. (amended) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim ~~25~~ 24.

Claim 27. (previously presented) A host cell according to claim 26, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

Claim 28. (previously presented) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid according to claim 24 under conditions in vitro, in vivo or in situ, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claims 29-101. (canceled).

Claim 102 (Newly added) An isolated nucleic acid encoding a human monoclonal antibody comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

Claim 103. (newly added). An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 102.

Claim 104. (newly added) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 102.

Claim 105. (newly added ) A host cell according to claim 104, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

Claim 106. (newly added) A method for producing at least one anti-dual integrin antibody, comprising translating a nucleic acid according to claim 102 under conditions in vitro, in vivo or in situ, such that the dual integrin antibody is expressed in detectable or recoverable amounts.

Claim 107. (newly added) An isolated nucleic acid according to claim 102 wherein the antibody completely inhibits M21 cell adhesion to vitronectin.

Claim 108. (newly added) An isolated nucleic acid according to claim 102 wherein the antibody comprises a human IgG heavy chain and a human kappa light chain.

Claim 109. (newly added ) An isolated nucleic acid according to claim 102 wherein the antibody comprises an IgG1 or IgG3 heavy chain.

Claim 110 (newly added) An isolated nucleic acid according to claim 102 wherein the antibody is an IgG1kappa antibody.